News | April 13, 2011

Enrollment Begins for Bare-Metal Stent Trial

April 13, 2011 – Patient enrollment has begun for the SuperNOVA clinical trial. It will examine the safety and effectiveness of Boston Scientific’s Innova self-expanding bare-metal stent in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).

Enrollment is planned for up to 300 patients at 50 sites in the United States, Canada and Europe. The first patient was enrolled in the trial by Subhash Banerjee, M.D., associate professor of medicine and chief of cardiology at the VA Medical Center in Dallas, Texas.

The stent is designed to treat peripheral vascular lesions in arteries above the knee, specifically the SFA and PPA. It consists of a nitinol, self-expanding bare-metal stent loaded on an advanced low-profile delivery system. The architecture features a closed cell design at each end of the stent for improved radial force and fracture resistance, and an open cell design along the stent body that doesn't compromise flexibility. Stent deliverability is enhanced with a tri-axial catheter shaft designed to provide added support and placement accuracy, as well as dual deployment options and radiopaque markers to enhance ease of use. The stent is 6 French compatible and ranges from 5 to 8 mm in diameter and 20 to 200 mm in length.

"Treating arteries above the knee is difficult because the challenging anatomy can lead to stent fractures and higher restenosis rates," said Richard J. Powell, M.D., section chief of vascular surgery at Dartmouth-Hitchcock Medical Center in Lebanon, N.H., and global principal investigator of the SuperNOVA trial. "I believe the Innova Stent offers a unique design that provides excellent radial strength while remaining flexible and durable, which is critical to sustaining patency in treated SFA and PPA lesions."

"The Innova Stent is engineered to offer an advanced solution in treating blockages within these critical arteries," said Joe Fitzgerald, senior vice president and president of Boston Scientific's endovascular unit. "Its design is intended to improve blood flow and provide greater long-term stent durability, ultimately improving the overall quality of life for patients with peripheral artery disease."

The system received CE mark in March, and the company plans to begin marketing the product in the EU and other countries in the second quarter of 2011. In the United States, it is an investigational device, limited by applicable law to investigational use only and not available for sale.

For more information: www.bostonscientific.com

Related Content

First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Medtronic Launches Concerto 3-D Detachable Coil System
News | Embolization devices| October 16, 2017
October 16, 2017 — Medtronic announced the launch of the Concerto 3-D Detachable Coil System at the Cardiovascular an
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Avinger Receives CE Mark for In-Stent Restenosis Indication With Pantheris Image-Guided Atherectomy
Technology | Atherectomy Devices| September 29, 2017
Avinger Inc. recently announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
Overlay Init